Oct
12
2022
On demand
Predicting patient response to immune targeted therapies via interrogation of the TME
Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
More accurately predicting which patients will benefit from immune targeted therapies, including checkpoint inhibitors, remains a crucial goal for the I–O field.
This webinar will provide an overview of an RNA-based investigational tumor microenvironment (TME) panel to better interrogate tumor biology and support multiple oncology therapeutics – particularly immune checkpoint inhibitors and anti-angiogenic agents – across a range of tumor types.
New translational data on predicting benefit from maintenance durvalumab after first-line chemotherapy in esophagogastric adenocarcinoma will be discussed, along with the potential for companion diagnostic development in support of clinical development.
- The broad clinical and research applications of an RNA-based TME assay for I–O applications
- How interrogation of the TME via RNA signatures can improve the identification of patients who might benefit from multiple oncology therapeutics, particularly immune checkpoint inhibitors and anti-angiogenic agents
- Future development of the Xerna TME Panel as an RUO, CTA and CDx assay platform
SPEAKERS
You might also like
The role of AI in predicting stem cell donor availability
A Madbouly, J Mcatee, B Shaffer et al.
31 January
Watch
Rapid CAR-T cells: Accelerating manufacturing to enable fast transition of CAR-T cell therapies to the clinic
Tamara Laskowski, Kelly Purpura
7 December 2023
Watch
Empowering patient care: in-process and quality control solutions for cellular therapies
Christin Tischner, Simon Lennartz
23 May
Watch
Streamlining immune cell therapy manufacturing workflows with single-use cytokines
Gabriella Perell
19 June
Watch
Optimizing access to high quality, standardized, and compliant leukopaks for the development and commercialization of allogeneic therapies
Makensie Becker
18 April
Watch